Anti‐tumor effects of recombinant human macrophage colony‐stimulating factor, alone or in combination with local irradiation, in mice inoculated with lewis lung carcinoma cells

Li Lu, Rong‐Nian ‐N Shen, Zhong‐Hua ‐H Lin, Sharon L. Aukerman, Peter Ralph, Hal E. Broxmeyer

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Recombinant human (rhu) macrophage colony-stimulating factor (M-CSF) was evaluated for efficacy, either alone or in combination with local X-irradiation (LR), in mice inoculated subcutaneously (s.c.) with Lewis lung carcinoma (LLC) cells. The size of the primary tumor and numbers of lung metastases, 21 days after tumor inoculation and 15 days after the start of treatment, were reduced by 87% in tumor-bearing mice treated with 20 μg/dose M-CSF s.c. twice a day for 5 days. LR (800 cGy) to the tumor once a week for 2 weeks had a moderate anti-tumor effect and enhanced the ant-tumor effect of M-CSF. Hematological parameters, including nucleated cellularity in peripheral blood, femoral marrow, spleen and peritoneal exudate, as well as marrow and splenic granulocyte-macrophage progenitor cells, and numbers of splenic Thy1.2+ cell and peritoneal mast cells, were perturbed in LLC-bearing mice, and were influenced by treatment with M-CSF and LR. Treatment with M-CSF plus LR, but not with either agent alone, was associated with a significant, although slight, enhancement in survival time for LLC-bearing mice. Inability to obtain a better survival-enhancing effect appeared to be related to the limited treatment, since the anti-tumor effects of M-CSF were more notable early on in disease progression and were related to the dose of M-CSF used. The effects of M-CSF were most probably indirect ones on the host immune system. M-CSF, in combination with LR, may be of benefit in the treatment of human tumors that have metastatic potential.

Original languageEnglish (US)
Pages (from-to)143-147
Number of pages5
JournalInternational Journal of Cancer
Volume47
Issue number1
DOIs
StatePublished - Jan 2 1991

Fingerprint

Lewis Lung Carcinoma
Macrophage Colony-Stimulating Factor
Neoplasms
Bone Marrow
Granulocyte-Macrophage Progenitor Cells
Survival
Ants
Exudates and Transudates
Thigh
Mast Cells
Disease Progression
Immune System
Spleen
Cell Count
Neoplasm Metastasis
Lung

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Anti‐tumor effects of recombinant human macrophage colony‐stimulating factor, alone or in combination with local irradiation, in mice inoculated with lewis lung carcinoma cells. / Lu, Li; Shen, Rong‐Nian ‐N; Lin, Zhong‐Hua ‐H; Aukerman, Sharon L.; Ralph, Peter; Broxmeyer, Hal E.

In: International Journal of Cancer, Vol. 47, No. 1, 02.01.1991, p. 143-147.

Research output: Contribution to journalArticle

@article{e0d4682a516c4fe99fd6111f6547ecd2,
title = "Anti‐tumor effects of recombinant human macrophage colony‐stimulating factor, alone or in combination with local irradiation, in mice inoculated with lewis lung carcinoma cells",
abstract = "Recombinant human (rhu) macrophage colony-stimulating factor (M-CSF) was evaluated for efficacy, either alone or in combination with local X-irradiation (LR), in mice inoculated subcutaneously (s.c.) with Lewis lung carcinoma (LLC) cells. The size of the primary tumor and numbers of lung metastases, 21 days after tumor inoculation and 15 days after the start of treatment, were reduced by 87{\%} in tumor-bearing mice treated with 20 μg/dose M-CSF s.c. twice a day for 5 days. LR (800 cGy) to the tumor once a week for 2 weeks had a moderate anti-tumor effect and enhanced the ant-tumor effect of M-CSF. Hematological parameters, including nucleated cellularity in peripheral blood, femoral marrow, spleen and peritoneal exudate, as well as marrow and splenic granulocyte-macrophage progenitor cells, and numbers of splenic Thy1.2+ cell and peritoneal mast cells, were perturbed in LLC-bearing mice, and were influenced by treatment with M-CSF and LR. Treatment with M-CSF plus LR, but not with either agent alone, was associated with a significant, although slight, enhancement in survival time for LLC-bearing mice. Inability to obtain a better survival-enhancing effect appeared to be related to the limited treatment, since the anti-tumor effects of M-CSF were more notable early on in disease progression and were related to the dose of M-CSF used. The effects of M-CSF were most probably indirect ones on the host immune system. M-CSF, in combination with LR, may be of benefit in the treatment of human tumors that have metastatic potential.",
author = "Li Lu and Shen, {Rong‐Nian ‐N} and Lin, {Zhong‐Hua ‐H} and Aukerman, {Sharon L.} and Peter Ralph and Broxmeyer, {Hal E.}",
year = "1991",
month = "1",
day = "2",
doi = "10.1002/ijc.2910470125",
language = "English (US)",
volume = "47",
pages = "143--147",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Anti‐tumor effects of recombinant human macrophage colony‐stimulating factor, alone or in combination with local irradiation, in mice inoculated with lewis lung carcinoma cells

AU - Lu, Li

AU - Shen, Rong‐Nian ‐N

AU - Lin, Zhong‐Hua ‐H

AU - Aukerman, Sharon L.

AU - Ralph, Peter

AU - Broxmeyer, Hal E.

PY - 1991/1/2

Y1 - 1991/1/2

N2 - Recombinant human (rhu) macrophage colony-stimulating factor (M-CSF) was evaluated for efficacy, either alone or in combination with local X-irradiation (LR), in mice inoculated subcutaneously (s.c.) with Lewis lung carcinoma (LLC) cells. The size of the primary tumor and numbers of lung metastases, 21 days after tumor inoculation and 15 days after the start of treatment, were reduced by 87% in tumor-bearing mice treated with 20 μg/dose M-CSF s.c. twice a day for 5 days. LR (800 cGy) to the tumor once a week for 2 weeks had a moderate anti-tumor effect and enhanced the ant-tumor effect of M-CSF. Hematological parameters, including nucleated cellularity in peripheral blood, femoral marrow, spleen and peritoneal exudate, as well as marrow and splenic granulocyte-macrophage progenitor cells, and numbers of splenic Thy1.2+ cell and peritoneal mast cells, were perturbed in LLC-bearing mice, and were influenced by treatment with M-CSF and LR. Treatment with M-CSF plus LR, but not with either agent alone, was associated with a significant, although slight, enhancement in survival time for LLC-bearing mice. Inability to obtain a better survival-enhancing effect appeared to be related to the limited treatment, since the anti-tumor effects of M-CSF were more notable early on in disease progression and were related to the dose of M-CSF used. The effects of M-CSF were most probably indirect ones on the host immune system. M-CSF, in combination with LR, may be of benefit in the treatment of human tumors that have metastatic potential.

AB - Recombinant human (rhu) macrophage colony-stimulating factor (M-CSF) was evaluated for efficacy, either alone or in combination with local X-irradiation (LR), in mice inoculated subcutaneously (s.c.) with Lewis lung carcinoma (LLC) cells. The size of the primary tumor and numbers of lung metastases, 21 days after tumor inoculation and 15 days after the start of treatment, were reduced by 87% in tumor-bearing mice treated with 20 μg/dose M-CSF s.c. twice a day for 5 days. LR (800 cGy) to the tumor once a week for 2 weeks had a moderate anti-tumor effect and enhanced the ant-tumor effect of M-CSF. Hematological parameters, including nucleated cellularity in peripheral blood, femoral marrow, spleen and peritoneal exudate, as well as marrow and splenic granulocyte-macrophage progenitor cells, and numbers of splenic Thy1.2+ cell and peritoneal mast cells, were perturbed in LLC-bearing mice, and were influenced by treatment with M-CSF and LR. Treatment with M-CSF plus LR, but not with either agent alone, was associated with a significant, although slight, enhancement in survival time for LLC-bearing mice. Inability to obtain a better survival-enhancing effect appeared to be related to the limited treatment, since the anti-tumor effects of M-CSF were more notable early on in disease progression and were related to the dose of M-CSF used. The effects of M-CSF were most probably indirect ones on the host immune system. M-CSF, in combination with LR, may be of benefit in the treatment of human tumors that have metastatic potential.

UR - http://www.scopus.com/inward/record.url?scp=0025966030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025966030&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910470125

DO - 10.1002/ijc.2910470125

M3 - Article

C2 - 1985870

AN - SCOPUS:0025966030

VL - 47

SP - 143

EP - 147

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -